References

Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., Lander, E. S., Voytas, D. F., Ting, A. Y., & Zhang, F. (2017). RNA targeting with CRISPR–Cas13. Nature, 550(7675), 280–284. https://doi.org/10.1038/nature24049

Adamson, B., Norman, T. M., Jost, M., Cho, M. Y., Nuñez, J. K., Chen, Y., Villalta, J. E., Gilbert, L. A., Horlbeck, M. A., Hein, M. Y., Pak, R. A., Gray, A. N., Gross, C. A., Dixit, A., Parnas, O., Regev, A., & Weissman, J. S. (2016). A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response. Cell, 167(7), 1867–1882.e21. https://doi.org/10.1016/j.cell.2016.11.048

Alaburde, A., Ivaska, J., Kaspute, G., & Ivaskiene, T. (2025). Impact of regulatory measures on the approval timelines of advanced therapy medicinal products by the European Medicines Agency. Frontiers in Medicine, 12, 1623689. https://doi.org/10.3389/fmed.2025.1623689

Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., Islam, S. M. A., Lopez-Bigas, N., Klimczak, L. J., McPherson, J. R., Morganella, S., Sabarinathan, R., Wheeler, D. A., Mustonen, V., PCAWG Mutational Signatures Working Group, … Stratton, M. R. (2020). The repertoire of mutational signatures in human cancer. Nature, 578, 94–101. https://doi.org/10.1038/s41586-020-1943-3

Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H., & Gorodkin, J. (2018). CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters. Genome Biology, 19, 177. https://doi.org/10.1186/s13059-018-1534-x

Allen, F., Crepaldi, L., Alsinet, C., Strong, A. J., Kleshchevnikov, V., De Angeli, P., Páleníková, P., Khodak, A., Kiselev, V., Kosicki, M., Bassett, A. R., Harding, H., Gaber, Y., Muñoz-Manchado, A. B., Barber, M., & Parts, L. (2019). Predicting the mutations generated by repair of Cas9-induced double-strand breaks. Nature Biotechnology, 37(1), 64–72. https://doi.org/10.1038/nbt.4317

Anderson, R. A., Mitchell, R. T., Kelsey, T. W., Spears, N., Telfer, E. E., & Wallace, W. H. B. (2015). Cancer treatment and gonadal function: Experimental and established strategies for fertility preservation in children and young adults. The Lancet Diabetes & Endocrinology, 3(7), 556–567. https://doi.org/10.1016/S2213-8587(15)00039-X

Angermueller, C., Dohan, D., Belanger, D., Deshpande, R., Murphy, K., & Colwell, L. (2020). Model-based reinforcement learning for biological sequence design. Proceedings of the International Conference on Learning Representations (ICLR).

Angermueller, C., Dohan, D., Belanger, D., Murphy, K., & Colwell, L. J. (2020). Population-based black-box optimization for biological sequence design. Nature Methods, 17, 1173–1180. https://doi.org/10.1038/s41592-020-0965-8

Anzalone, A. V., Gao, X. D., Podracky, C. J., Nelson, A. T., Koblan, L. W., Raguram, A., Levy, J. M., Merber, J. M., Cho, T. C., & Liu, D. R. (2022). Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nature Biotechnology, 40(5), 731–740. https://doi.org/10.1038/s41587-021-01133-w

Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), 149–157. https://doi.org/10.1038/s41586-019-1711-4

Arbab, M., Shen, M. W., Mok, B., Wilson, C., Matuszek, Ż., Cassa, C. A., & Liu, D. R. (2020). Determinants of base editing outcomes from target library analysis and machine learning. Cell, 182(2), 463–480.e30. https://doi.org/10.1016/j.cell.2020.05.037

Arnold, F. H. (2018). Directed evolution: Bringing new chemistry to life. Angewandte Chemie International Edition, 57(16), 4143–4148. https://doi.org/10.1002/anie.201708408

Arnstein, S. R. (1969). A ladder of citizen participation. Journal of the American Institute of Planners, 35(4), 216–224. https://doi.org/10.1080/01944366908977225

Asch, A. (2003). Disability equality and prenatal testing: Contradictory or compatible? In Florida state university law review (Vol. 30, pp. 315–342).

ASCO Post Staff. (2026). New European project cluster EARLYSCAN launched to advance early detection of heritable cancers. https://ascopost.com/news/february-2026/new-european-project-cluster-earlyscan-launched-to-advance-early-detection-of-heritable-cancers/

Athey, S., Tibshirani, J., & Wager, S. (2019). Generalized random forests. The Annals of Statistics, 47(2), 1148–1178. https://doi.org/10.1214/18-AOS1709

Bae, S., Park, J., & Kim, J.-S. (2014). Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics, 30(10), 1473–1475. https://doi.org/10.1093/bioinformatics/btu048

Baltussen, R., Jansen, M. P. M., Bijl, N. de, & Stolk, E. A. (2019). Value assessment frameworks for HTA agencies: The organization of evidence-informed deliberative processes. Value in Health, 22(2), 213–220. https://doi.org/10.1016/j.jval.2018.11.003

Barker, A. D., Sigman, C. C., Kelloff, G. J., Hylton, N. M., Berry, D. A., & Esserman, L. J. (2009). I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics, 86(1), 97–100. https://doi.org/10.1038/clpt.2009.68

Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709–1712. https://doi.org/10.1126/science.1138140

Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197–198. https://doi.org/10.1001/jama.2017.7156

Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427–436. https://doi.org/10.1002/pds.1742

Baylis, F., Darnovsky, M., Hasson, K., & Krahn, T. M. (2020). Human germline and heritable genome editing: The global policy landscape. The CRISPR Journal, 3(5), 365–377. https://doi.org/10.1089/crispr.2020.0082

Baylis, F., & Ikemoto, L. (2017). The Council of Europe and the prohibition on human germline genome editing. EMBO Reports, 18(12), 2084–2085. https://doi.org/10.15252/embr.201745343

Beam Therapeutics. (2025). Beam Therapeutics reports clinical data demonstrating first-ever CRISPR correction of a disease-causing mutation in patients with alpha-1 antitrypsin deficiency. Corporate data presentation.

Beauchamp, T. L., & Childress, J. F. (2019). Principles of biomedical ethics (8th ed.). Oxford University Press.

Beckert, J. (2016). Imagined futures: Fictional expectations and capitalist dynamics. Harvard University Press.

Bellinger, A. M. et al. (2023). Safety and pharmacodynamic effects of VERVE-101, an investigational DNA base editing medicine designed to durably inactivate the PCSK9 gene and lower LDL cholesterol – interim results of the Phase 1b Heart-1 trial. Circulation. https://www.vervetx.com/sites/default/files/2023-11/Verve_AHA_2023_LBS_for%20website.pdf

Benatar, S. R. (2003). Bioethics: Power and injustice: IAB presidential address. Bioethics, 17(5–6), 387–398. https://doi.org/10.1111/1467-8519.00355

Benjamin, R. (2019). Race after technology: Abolitionist tools for the New Jim Code. Polity Press.

Bernsen, M. R., Zanden, S. Y. van der, Heuvel, J. J. M. W. van den, & Masereeuw, R. (2020). Pharmacogenomics as a tool to limit acute and long-term adverse effects of chemotherapeutics. Frontiers in Pharmacology, 11, 1184. https://doi.org/10.3389/fphar.2020.01184

Borup, M., Brown, N., Konrad, K., & Van Lente, H. (2006). The sociology of expectations in science and technology. Technology Analysis & Strategic Management, 18(3–4), 285–298. https://doi.org/10.1080/09537320600777002

Bostrom, N. (2003). The transhumanist FAQ: A general introduction. Journal of Evolution and Technology, 13(1). https://www.jetpress.org/volume13/bostrom-tsfaq.html

Bowker, G. C., & Star, S. L. (1999). Sorting things out: Classification and its consequences. MIT Press.

Brown, N. (2003). Hope against hype: Accountability in biopasts, presents and futures. Science Studies, 16(2), 3–21.

Bryant, D. H., Bashir, A., Sinai, S., Jain, N. K., Ogden, P. J., Riley, P. F., Church, G. M., Colwell, L. J., & Kelsic, E. D. (2021). Deep diversification of an AAV capsid protein by machine learning. Nature Biotechnology, 39, 691–696. https://doi.org/10.1038/s41587-020-00793-4

Buchanan, A., Brock, D. W., Daniels, N., & Wikler, D. (2000). From chance to choice: Genetics and justice. Cambridge University Press. https://doi.org/10.1017/CBO9780511806940

Byrne, F. et al. (2024). Prediction and prevention of late effects in AYA cancer survivors: The PredictAYA project. European Commission Horizon Europe Project. https://doi.org/10.3030/101214879

Calabrese, C., Amin, A., & Engel, K. (2020). Framing CRISPR: How media shape public understanding of gene editing. Public Understanding of Science, 29(5), 492–510. https://doi.org/10.1177/0963662520916775

Callon, M., & Rabeharisoa, V. (2003). Research “in the wild” and the shaping of new social identities. Technology in Society, 25(2), 193–204. https://doi.org/10.1016/S0160-791X(03)00021-6

Campa, C. C., Weisbach, N. R., Santinha, A. J., Incarnato, D., & Platt, R. J. (2019). Multiplexed genome engineering by Cas12a and CRISPR arrays encoded on single transcripts. Nature Methods, 16(9), 887–893. https://doi.org/10.1038/s41592-019-0508-6

Cavazzana, M., & Mavilio, F. (2020). The role of conditioning in hematopoietic stem-cell gene therapy. Gene Therapy, 27, 1–10. https://doi.org/10.1038/s41434-019-0103-1

CDBIO. (2022). Genome editing technologies: Final conclusions of the re-examination of article 13 of the oviedo convention. Council of Europe. https://www.coe.int/en/web/human-rights-and-biomedicine/-/genome-editing-technologies-final-conclusions-of-the-re-examination-of-article-13-of-the-oviedo-convention

Chandak, P., Huang, K., & Zitnik, M. (2023). Building a knowledge graph to enable precision medicine. Scientific Data, 10, 67. https://doi.org/10.1038/s41597-023-01960-3

Chari, R., Mali, P., Moosburner, M., & Church, G. M. (2015). Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nature Methods, 12(9), 823–826. https://doi.org/10.1038/nmeth.3473

Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Buj, N. L., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Henle, J., Søndergaard, J. N., & Porteus, M. H. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine, 25(2), 249–254. https://doi.org/10.1038/s41591-018-0326-x

Charon, R. (2006). Narrative medicine: Honouring the stories of illness. Oxford University Press.

Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science, 360(6387), 436–439. https://doi.org/10.1126/science.aar6245

Chen, P. J., Hussmann, J. A., Yan, J., Knipping, F., Ravisankar, P., Chen, P.-F., Chen, C., Nelson, J. W., Newby, G. A., Sahin, M., Osborn, M. J., Weissman, J. S., Adamson, B., & Liu, D. R. (2021). Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell, 184(22), 5635–5652. https://doi.org/10.1016/j.cell.2021.09.018

Chen, W., McKenna, A., Schreiber, J., Haeussler, M., Yin, Y., Agarwal, V., Noble, W. S., & Shendure, J. (2019). Massively parallel profiling and predictive modeling of the outcomes of CRISPR/Cas9-mediated double-strand break repair. Nucleic Acids Research, 47(15), 7989–8003. https://doi.org/10.1093/nar/gkz487

Cheng, J., Novati, G., Pan, J., Bycroft, C., Žemgulytė, A., Applebaum, T., Pritzel, A., Wong, L. H., Zielinski, M., Sargeant, T., Schneider, R. G., Senior, A. W., Jumper, J., Hassabis, D., Kohli, P., & Avsec, Ž. (2023). Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science, 381(6664), eadg7492. https://doi.org/10.1126/science.adg7492

Chernozhukov, V., Chetverikov, D., Demirer, M., Duflo, E., Hansen, C., Newey, W., & Robins, J. (2018). Double/debiased machine learning for treatment and structural parameters. The Econometrics Journal, 21(1), C1–C68. https://doi.org/10.1111/ectj.12097

Chiesa, R., Georgiadis, C., Syed, F., et al. (2023). Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. New England Journal of Medicine, 389(10), 899–910. https://doi.org/10.1056/NEJMoa2300709

Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013). Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nature Biotechnology, 31(3), 230–232. https://doi.org/10.1038/nbt.2507

Choi, S. W., Reise, S. P., Pilkonis, P. A., Hays, R. D., & Cella, D. (2010). Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Quality of Life Research, 19(1), 125–136. https://doi.org/10.1007/s11136-009-9560-5

Chu, H. Y., Fong, J. H. C., Thean, D. G. L., Zhou, P., Fung, F. K. C., Huang, Y., & Wong, A. S. L. (2024). Accurate top protein variant discovery via low-N pick-and-validate machine learning. Cell Systems, 15(2), 193–203.e6. https://doi.org/10.1016/j.cels.2024.01.002

Chuai, G., Ma, H., Yan, J., Chen, M., Hong, N., Xue, D., Zhou, C., Zhu, C., Chen, K., Duan, B., Gu, F., Qu, S., Huang, D., Wei, J., & Liu, Q. (2018). DeepCRISPR: Optimized CRISPR guide RNA design by deep learning. Genome Biology, 19, 80. https://doi.org/10.1186/s13059-018-1459-4

Collingridge, D. (1980b). The social control of technology. Frances Pinter.

Collingridge, D. (1980a). The social control of technology. Frances Pinter.

Collins, H. M., & Evans, R. (2002). The third wave of science studies: Studies of expertise and experience. Social Studies of Science, 32(2), 235–296. https://doi.org/10.1177/0306312702032002003

Collins, H. M., & Yearley, S. (1992). Epistemological chicken. In A. Pickering (Ed.), Science as practice and culture (pp. 301–326). University of Chicago Press.

Comandè, G. (2017). Regulating algorithms’ regulation? First ethico-legal principles, problems, and opportunities of algorithms. In T. Cerquitelli, D. Quercia, & F. Pasquale (Eds.), Transparent data mining for big and small data (Vol. 9853, pp. 169–206). Springer International Publishing. https://doi.org/10.1007/978-3-319-54024-5_8

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819–823. https://doi.org/10.1126/science.1231143

Consortium, P., Dorp, W. van, Mulder, R. L., Heuvel-Eibrink, M. M. van den, et al. (2024). Genetic determinants of gonadal impairment after childhood cancer treatment. Nature Medicine, 30, 1123–1134. https://doi.org/10.1038/s41591-024-02987-3

CORDIS. (2025). Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH syndrome (PREDI-LYNCH). https://doi.org/10.3030/101213916

Corral-Acero, J., Margara, F., Marciniak, M., Rodero, C., Lonber, F., Feng, Y., Gilbert, A., Fernandes, J. F., Bukhari, H. A., Wajdan, A., et al. (2020). The “digital twin” to enable the vision of precision cardiology. European Heart Journal, 41(48), 4556–4564. https://doi.org/10.1093/eurheartj/ehaa159

Corrigan-Curay, J., Sacks, L., & Woodcock, J. (2018). Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA, 320(9), 867–868. https://doi.org/10.1001/jama.2018.10136

Council of Europe. (1997). Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on human rights and biomedicine.

Court of Justice of the European Union. (2018). Judgment of 25 July 2018, Confédération paysanne and others, Case C-528/16, ECLI:EU:C:2018:583. https://infocuria.curia.europa.eu/tabs/document?source=document&docid=204387&doclang=EN

Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017). RNA editing with CRISPR–Cas13. Science, 358(6366), 1019–1027. https://doi.org/10.1126/science.aaq0180

Criminal law of the People’s Republic of China, article 336. (2021).

CRISPR Therapeutics. (2024). CRISPR therapeutics provides business update and reports fourth quarter and full year 2024 financial results. https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-provides-business-update-and-reports-fourth-quarter-and-full-year-2024-financial-results.

Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina, J. E., Hruban, C., White, J. R., Palsgrove, D. N., Niknafs, N., Anagnostou, V., Forde, P., Velculescu, V. E., et al. (2019). Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 570, 385–389. https://doi.org/10.1038/s41586-019-1272-6

Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: Monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472–484. https://doi.org/10.1038/nrclinonc.2013.110

Dalla-Torre, H., Gonzalez, L., Mendoza-Revilla, J., Lopez Carranza, N., Grzywaczewski, A. H., Oteri, F., Dallago, C., Trop, E., Almeida, B. P. de, Sirelkhatim, H., Richard, G., Skwark, M., Beguir, K., Lopez, M., & Pierrot, T. (2025). Nucleotide transformer: Building and evaluating robust foundation models for human genomics. Nature Methods, 22(2), 287–297. https://doi.org/10.1038/s41592-024-02523-z

Daniels, N. (2000). Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics, 9(3), 309–322. https://doi.org/10.1017/S0963180100903037

Darnovsky, M. (2019). The case against designer babies: The perils of heritable genome editing. Nature Biotechnology, 37(9), 983.

Datlinger, P., Rendeiro, A. F., Schmidl, C., Krausgruber, T., Traxler, P., Klughammer, J., Schuster, L. C., Kuchler, A., Alpar, D., & Bock, C. (2017). Pooled CRISPR screening with single-cell transcriptome readout. Nature Methods, 14(3), 297–301. https://doi.org/10.1038/nmeth.4177

Davies, N. M., Holmes, M. V., & Davey Smith, G. (2018). Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ, 362, k601. https://doi.org/10.1136/bmj.k601

Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011). CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 471(7340), 602–607. https://doi.org/10.1038/nature09886

Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., Bhatt, H. R., et al. (2016). Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nature Biotechnology, 34(2), 204–209. https://doi.org/10.1038/nbt.3440

Dewar, E. O., Ahn, C., Eraj, S., Mahal, B. A., & Sanford, N. N. (2021). Psychological distress and cognition among long-term survivors of adolescent and young adult cancer in the USA. Journal of Cancer Survivorship, 15, 776–784. https://doi.org/10.1007/s11764-020-00986-0

Dinh, C. T., Tran, N. H., & Nguyen, T. D. (2020). Personalized federated learning with moreau envelopes. NeurIPS ’20, 21394–21405. https://dl.acm.org/doi/abs/10.5555/3495724.3497520

Dixit, A., Parnas, O., Li, B., Chen, J., Fulco, C. P., Jerber, J., Raychowdhury, R., Weissman, J. S., Regev, A., & Hacohen, N. (2016). Perturb-seq: Dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell, 167(7), 1853–1866.e17. https://doi.org/10.1016/j.cell.2016.11.038

Dixit, A., Parnas, O., Li, B., Chen, J., Fulco, C. P., Jerby-Arnon, L., Marjanovic, N. D., Dionne, D., Burks, T., Raychowdhury, R., Adamson, B., Norman, T. M., Lander, E. S., Weissman, J. S., Friedman, N., & Regev, A. (2016). Perturb-seq: Dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. Cell, 167(7), 1853–1866.e17. https://doi.org/10.1016/j.cell.2016.11.038

Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., Virgin, H. W., Listgarten, J., & Root, D. E. (2016). Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nature Biotechnology, 34(2), 184–191. https://doi.org/10.1038/nbt.3437

Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014). Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nature Biotechnology, 32(12), 1262–1267. https://doi.org/10.1038/nbt.3026

Dominguez-Valentin, M., Sampson, J. R., Seppälä, T. T., & Ten Broeke, P., Sanne W and";";"; "; Møller. (2020). Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 22(1), 15–25. https://doi.org/10.1038/s41436-019-0596-9

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford University Press.

Duan, D. (2018). Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Molecular Therapy, 26(10), 2337–2356. https://doi.org/10.1016/j.ymthe.2018.07.011

EARLYSCAN Cluster. (2026). New European project cluster EARLYSCAN launched to advance early detection of heritable cancers. ASCO Post, February 2026; press release via PREDI-LYNCH website. https://ascopost.com/news/february-2026/new-european-project-cluster-earlyscan-launched-to-advance-early-detection-of-heritable-cancers/

Editas Medicine. (2023). Editas medicine announces strategic pipeline prioritization. Press release. https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-strategic-updates-and-portfolio

Edwards, P. N. (2010). A vast machine: Computer models, climate data, and the politics of global warming. MIT Press.

Epstein, S. (1996). Impure science: AIDS, activism, and the politics of knowledge. University of California Press.

European Commission. (2017). EudraLex volume 4, part IV: Guidelines on good manufacturing practice specific to advanced therapy medicinal products.

European Commission. (2021). Horizon Europe cluster 1 health: Annex I — key strategic orientations.

European Commission. (2024). EU Mission: cancer. https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/eu-missions-horizon-europe/eu-mission-cancer_en

European Commission. (2025a). European Health Data Space implementation timeline. https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space-regulation-ehds_en

European Commission. (2025b). Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH syndrome – CORDIS. https://cordis.europa.eu/project/id/101213916.

European Medicines Agency. (2023). Reflection paper on the use of real-world data in non-interventional studies to generate real-world evidence. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence_en.pdf.

European Medicines Agency. (2025a). CAT quarterly highlights and approved ATMPs, December 2025. https://www.ema.europa.eu/en/documents/committee-report/cat-quarterly-highlights-approved-atmps-december-2025_en.pdf

European Medicines Agency. (2025b). Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials.

European Parliament and Council. (2001). Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms: L 106 (pp. 1–39). Official Journal of the European Communities. https://eur-lex.europa.eu/eli/dir/2001/18/oj/eng

European Parliament and Council. (2014). Regulation (EU) no 536/2014 on clinical trials on medicinal products for human use: L 158 (pp. 1–76). Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32014R0536

European Parliament and Council. (2024). Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (AI act): L. Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689

European Parliament and Council. (2025). Regulation (EU) 2025/327 on the european health data space. Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32025R0327

European Parliament and Council of the European Union. (2007). Regulation (EC) no 1394/2007 on advanced therapy medicinal products: L 324 (pp. 121–137). Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32007R1394

European Parliament and Council of the European Union. (2016). Regulation (EU) 2016/679 (general data protection regulation). L 119, 1–88. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679

European Parliament and Council of the European Union. (2017a). Regulation (EU) 2017/745 on medical devices: L 117 (pp. 1–175). Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0745

European Parliament and Council of the European Union. (2017b). Regulation (EU) 2017/746 on in vitro diagnostic medical devices: L 117 (pp. 176–332). Official Journal of the European Union. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746

European Parliament and Council of the European Union. (2024). Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (AI Act). Official Journal of the European Union, L series.

European Parliament and Council of the European Union. (2025). Regulation (EU) 2025/327 establishing the European Health Data Space. Official Journal of the European Union.

Faden, R. R., & Beauchamp, T. L. (1986). A history and theory of informed consent. Oxford University Press.

FDA, Health Canada, & MHRA. (2021). Good machine learning practice for medical device development: Guiding principles.

Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J., Galver, L., Kelley, R., Karlsson, A., Santos, R., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017). The druggable genome and support for target identification and validation in drug development. Science Translational Medicine, 9(383), eaag1166. https://doi.org/10.1126/scitranslmed.aag1166

Findlay, G. M., Daza, R. M., Martin, B., Zhang, M. D., Leith, A. P., Gasperini, M., Janizek, J. D., Huang, X., Starita, L. M., & Shendure, J. (2018). Accurate classification of BRCA1 variants with saturation genome editing. Nature, 562(7726), 217–222. https://doi.org/10.1038/s41586-018-0461-z

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., Heteren, J. van, Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., Shah, R. R., Shah, A., Ling, D., Growe, J., Pink, M., Rohde, E., Wood, K. M., Salomon, W. E., Harrington, W. F., … Morrissey, D. V. (2018). A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Reports, 22(9), 2227–2235. https://doi.org/10.1016/j.celrep.2018.02.014

Forget, B. G. (1998). Molecular basis of hereditary persistence of fetal hemoglobin. Annals of the New York Academy of Sciences, 850(1), 38–44. https://doi.org/10.1111/j.1749-6632.1998.tb10460.x

Frangoul, H. et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054

Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., Fuente, J. de la, Gruber, S., Handgretinger, R., et al. (2021). CRISPR–Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054

Frangoul, H., Locatelli, F., Sharma, A., et al. (2024). Exagamglogene autotemcel for severe sickle cell disease. New England Journal of Medicine, 390(18), 1649–1662. https://doi.org/10.1056/NEJMoa2309676

Fricker, M. (2007). Epistemic injustice: Power and the ethics of knowing. Oxford University Press. https://doi.org/10.1093/acprof:oso/9780198237907.001.0001

Fukuyama, F. (2002). Our posthuman future: Consequences of the biotechnology revolution. Farrar, Straus; Giroux.

Garrison, L. P., Jiao, B., & Engel-Nitz, N. M. (2021). Gene therapy may not be as expensive as people think: Challenges in assessing the value of single and short-term therapies. Journal of Managed Care & Specialty Pharmacy, 27(5), 674–681. https://doi.org/10.18553/jmcp.2021.27.5.674

Gasperini, M., Hill, A. J., McFaline-Figueroa, J. L., Martin, B., Kim, S., Zhang, M. D., Jackson, D., Leith, A., Schreiber, J., Noble, W. S., Trapnell, C., Ahfeldt, T., & Shendure, J. (2019). A genome-wide framework for mapping gene regulation via cellular genetic screens. Cell, 176(1–2), 377–390.e19. https://doi.org/10.1016/j.cell.2018.11.029

Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017). Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature, 551(7681), 464–471. https://doi.org/10.1038/nature24644

Georgiadis, A., Durham, J. N., Keefer, L. A., Bartlett, B. R., Zielonka, M., Murphy, D., White, J. R., Lu, S., Verner, E. L., Rber, F., Paschen, A., Diaz, L. A., Silliman, N., & Velculescu, V. E. (2019). Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade. Clinical Cancer Research, 25(23), 7024–7034. https://doi.org/10.1158/1078-0432.CCR-19-1372

Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154(2), 442–451. https://doi.org/10.1016/j.cell.2013.06.044

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502. https://doi.org/10.1056/NEJMoa2107454

Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Hutchaleelaha, A., Beattie, B. J., … Sardh, E. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493–502. https://doi.org/10.1056/NEJMoa2107454

Goddard, K., Roudsari, A., & Wyatt, J. C. (2012). Automation bias: A systematic review of frequency, effect mediators, and mitigators. Journal of the American Medical Informatics Association, 19(1), 121–127. https://doi.org/10.1136/amiajnl-2011-000089

Goldsack, J. C., Ernst, S., Dockendorf, M. F., Perumal, T. M., & Vandendriessche, B. (2023). Digital endpoints in clinical trials: Building the business case for systematic adoption. Nature, 620, 109–118. https://doi.org/10.1038/d41573-026-00033-5

Gonatopoulos-Pournatzis, T., Aregger, M., Brown, K. R., Farhangmehr, S., Braunschweig, U., Ward, H. N., Ha, K. C. H., Weiss, A., Billmann, M., Durbic, T., Myers, C. L., Blencowe, B. J., & Moffat, J. (2020). Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9–Cas12a platform. Nature Biotechnology, 38, 638–648. https://doi.org/10.1038/s41587-020-0437-z

González, J., Dai, Z., Hennig, P., & Lawrence, N. (2016). Batch Bayesian optimization via local penalization. Proceedings of the 19th International Conference on Artificial Intelligence and Statistics (AISTATS), 648–657. https://proceedings.mlr.press/v51/gonzalez16a.pdf

Gootenberg, J. S., Abudayyeh, O. O., Lee, J. W., Essletzbichler, P., Dy, A. J., Joung, J., Verdine, V., Donghia, N., Daringer, N. M., Freije, C. A., Myhrvold, C., Bhatt, R. P., Livny, J., Regev, A., Koonin, E. V., Hung, D. T., Sabeti, P. C., Collins, J. J., & Zhang, F. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. Science, 356(6336), 438–442. https://doi.org/10.1126/science.aam9321

Government of Japan. (2013). Act on the safety of regenerative medicine. Act No. 85 of November 27, 2013. https://www.japaneselawtranslation.go.jp/en/laws/view/2837

Green, D. M., Nolan, V. G., Goodman, P. J., Whitton, J. A., Srivastava, D., Leisenring, W. M., Neglia, J. P., Sklar, C. A., Kaste, S. C., Hudson, M. M., Diller, L. R., Stovall, M., Donaldson, S. S., & Robison, L. L. (2014). The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure. Pediatric Blood & Cancer, 61(1), 53–67. https://doi.org/10.1002/pbc.24679

Guston, D. H. (2014). Understanding “anticipatory governance.” Social Studies of Science, 44(2), 218–242. https://doi.org/10.1177/0306312713508669

Habermas, J. (2003). The future of human nature. Polity Press.

Haeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., Joly, J.-S., & Concordet, J.-P. (2016). Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biology, 17, 148. https://doi.org/10.1186/s13059-016-1012-2

Haraway, D. (1988). Situated knowledges: The science question in feminism and the privilege of partial perspective. Feminist Studies, 14(3), 575–599. https://doi.org/10.2307/3178066

Harden, K. P. (2021). The genetic lottery: Why DNA matters for social equality. Princeton University Press.

Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. Clinical Pharmacology & Therapeutics, 91(6), 1010–1021. https://doi.org/10.1038/clpt.2012.50

Hart, T., & Moffat, J. (2016). BAGEL: A computational framework for identifying essential genes from pooled library screens. BMC Bioinformatics, 17, 164. https://doi.org/10.1186/s12859-016-1015-8

Heijden, K. van der. (2005). Scenarios: The art of strategic conversation (2nd ed.). John Wiley & Sons.

Heil, B. J., Hoffman, M. M., Markowetz, F., Lee, S.-I., Greene, C. S., & Hicks, S. C. (2021). Reproducibility standards for machine learning in the life sciences. Nature Methods, 18(10), 1132–1135. https://doi.org/10.1038/s41592-021-01256-7

Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019). Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics, 20(2), 71–88. https://doi.org/10.1038/s41576-018-0071-5

Hernán, M. A., & Robins, J. M. (2020). Causal inference: What if. Chapman & Hall/CRC.

Hilton, I. B., D’Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology, 33(5), 510–517. https://doi.org/10.1038/nbt.3199

Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017). Systematic integration of biomedical knowledge prioritizes drugs for repurposing. eLife, 6, e26726. https://doi.org/10.7554/eLife.26726

Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021). Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development. Nature Reviews Cardiology, 18(6), 435–453. https://doi.org/10.1038/s41569-020-00493-1

Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., & Weissman, J. S. (2016). Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. eLife, 5, e19760. https://doi.org/10.7554/eLife.19760

Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., Cradick, T. J., Marraffini, L. A., Bao, G., & Zhang, F. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnology, 31(9), 827–832. https://doi.org/10.1038/nbt.2647

Huang, T. P., Zhao, K. T., Miller, S. M., Gaudelli, N. M., Oakes, B. L., Fellmann, C., Savage, D. F., & Liu, D. R. (2019). Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nature Biotechnology, 37(6), 626–631. https://doi.org/10.1038/s41587-019-0134-y

Hurlbut, J. B. (2017). Experiments in democracy: Human embryo research and the politics of bioethics. Columbia University Press.

Husson, O., Thomas, D. M., & Graaf, W. T. A. van der. (2023). Adolescent and young adult cancer survivorship and aging: The next step to take? Cancer Survivorship Research & Care, 1(1), 2234818. https://doi.org/10.1080/28352610.2023.2234818

International Council for Harmonisation. (2024). ICH Q5A(R2): Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.

Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169(12), 5429–5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987

Jansen, R., Embden, J. D. A. van, Gaastra, W., & Schouls, L. M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology, 43(6), 1565–1575. https://doi.org/10.1046/j.1365-2958.2002.02839.x

Jasanoff, S. (2004a). States of knowledge: The co-production of science and social order. Routledge.

Jasanoff, S. (2004b). States of knowledge: The co-production of science and social order. Routledge.

Jasanoff, S. (2004c). States of knowledge: The co-production of science and the social order. Routledge. https://doi.org/10.4324/9780203413845

Jasanoff, S. (2005b). Designs on nature: Science and democracy in Europe and the United States. Princeton University Press.

Jasanoff, S. (2005a). Designs on nature: Science and democracy in Europe and the United States. Princeton University Press.

Jasanoff, S., & Hurlbut, J. B. (2018b). A global observatory for gene editing. Nature, 555, 435–437. https://doi.org/10.1038/d41586-018-03270-w

Jasanoff, S., & Hurlbut, J. B. (2018a). A global observatory for gene editing. Nature, 555, 435–437. https://doi.org/10.1038/d41586-018-03270-w

Jasanoff, S., & Kim, S.-H. (Eds.). (2015b). Dreamscapes of modernity: Sociotechnical imaginaries and the fabrication of power. https://doi.org/10.7208/chicago/9780226276663.001.0001

Jasanoff, S., & Kim, S.-H. (2015a). Dreamscapes of modernity: Sociotechnical imaginaries and the fabrication of power. University of Chicago Press. https://doi.org/10.7208/chicago/9780226276663.001.0001

Jasin, M., & Rothstein, R. (2013). Repair of strand breaks by homologous recombination. Cold Spring Harbor Perspectives in Biology, 5(11), a012740. https://doi.org/10.1101/cshperspect.a012740

Ji, R., Chen, Q., & Zhang, Y. (2026). Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond. Cell Reports Medicine, 7(1), 102459. https://doi.org/10.1016/j.xcrm.2025.102459

Ji, Y., Zhou, Z., Liu, H., & Davuluri, R. V. (2021). DNABERT: Pre-trained bidirectional encoder representations from transformers model for DNA-language in genome. Bioinformatics, 37(15), 2112–2120. https://doi.org/10.1093/bioinformatics/btab083

Jiang, K., Yan, Z., Di Bernardo, M., Sgrizzi, S. R., Villiger, L., Kayabolen, A., Kim, B. J., Carscadden, J. K., Hiraizumi, M., Nishimasu, H., Gootenberg, J. S., & Abudayyeh, O. O. (2025). Rapid in silico directed evolution by a protein language model with EVOLVEpro. Science, 387(6732), eadr6006. https://doi.org/10.1126/science.adr6006

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žı́dek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., … Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596, 583–589. https://doi.org/10.1038/s41586-021-03819-2

Kang, T., Zhang, S., Tang, Y., Hruby, G. W., Rusanov, A., Elhadad, N., & Weng, C. (2017). EliIE: An open-source information extraction system for clinical trial eligibility criteria. Journal of the American Medical Informatics Association, 24(6), 1062–1071. https://doi.org/10.1093/jamia/ocx019

Karimireddy, S. P., Kale, S., Mohri, M., Reddi, S., Stich, S., & Suresh, A. T. (2020). SCAFFOLD: Stochastic controlled averaging for federated learning. Proceedings of the 37th International Conference on Machine Learning (ICML), 5132–5143.

Kass, L. R. (2002). Life, liberty and the defense of dignity: The challenge for bioethics. Encounter Books.

Katzman, J. L., Shaham, U., Cloninger, A., Bates, J., Jiang, T., & Kluger, Y. (2018). DeepSurv: Personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Medical Research Methodology, 18, 24. https://doi.org/10.1186/s12874-018-0482-1

Kay, L. E. (2000). Who wrote the book of life? A history of the genetic code. Stanford University Press.

Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 50(9), 1219–1224. https://doi.org/10.1038/s41588-018-0183-z

Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020). High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells. Nature Biomedical Engineering, 4(1), 111–124. https://doi.org/10.1038/s41551-019-0505-1

Kim, H. K., Min, S., Song, M., Jung, S., Choi, J. W., Kim, Y., Lee, S., Yoon, S., & Kim, H. H. (2019). SpCas9 activity prediction by DeepSpCas9, a deep learning-based model with high generalization performance. Science Advances, 5(11), eaax9249. https://doi.org/10.1126/sciadv.aax9249

Kim, H. K., Yu, G., Park, J., Min, S., Lee, S., Yoon, S., & Kim, H. H. (2021). Predicting the efficiency of prime editing guide RNAs in human cells. Nature Biotechnology, 39(2), 198–206. https://doi.org/10.1038/s41587-020-0677-y

Kim, H. K., Yu, G., Park, J., Min, S., Lee, S., Yoon, S., & Kim, H. H. (2023). Predicting the efficiency of prime editing guide RNAs in human cells. Nature Biotechnology, 41, 1135–1148. https://doi.org/10.1038/s41587-020-0677-y

Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., & Liu, M. C. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167–1177. https://doi.org/10.1016/j.annonc.2021.05.806

Kleinstiver, B. P. et al. (2025). Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning. Nature Biotechnology. https://doi.org/10.1038/s41586-025-09021-y

Klemm, S. L., Shipony, Z., & Greenleaf, W. J. (2019). Chromatin accessibility and the regulatory epigenome. Nature Reviews Genetics, 20(4), 207–220. https://doi.org/10.1038/s41576-018-0089-8

Klontzas, M. E., Akinci D’Antonoli, T., Curvo Semedo, L., et al. (2025). AI medical device post-market surveillance regulations: Consensus recommendations by the European Society of Radiology. Insights into Imaging, 16, 275. https://doi.org/10.1186/s13244-025-02146-8

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420–424. https://doi.org/10.1038/nature17946

Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., Nureki, O., & Zhang, F. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 517(7536), 583–588. https://doi.org/10.1038/nature14136

Konstantakos, V., Nentidis, A., Krithara, A., & Paliouras, G. (2022). CRISPRbench: A comprehensive benchmark for CRISPR-Cas guide RNA efficiency prediction. Briefings in Bioinformatics, 23(5), bbac377. https://doi.org/10.1093/bib/bbac377

Labun, K., Montague, T. G., Krause, M., Torres Cleuren, Y. N., Tjeldnes, H., & Valen, E. (2019). CHOPCHOP v3: Expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Research, 47(W1), W171–W174. https://doi.org/10.1093/nar/gkz365

Lander, E. S., Baylis, F., Zhang, F., Charpentier, E., Berg, P., et al. (2019). Adopt a moratorium on heritable genome editing. Nature, 567, 165–168. https://doi.org/10.1038/d41586-019-00726-5

Latour, B. (2004). Why has critique run out of steam? From matters of fact to matters of concern. Critical Inquiry, 30(2), 225–248. https://doi.org/10.1086/421123

Latour, B. (2005). Reassembling the social: An introduction to Actor-Network-Theory. Oxford University Press.

Laubenbacher, R., Mehrad, B., Shmulevich, I., & Trayanova, N. (2024). Digital twins in medicine. Nature Computational Science, 4(3), 184–191. https://doi.org/10.1038/s43588-024-00607-6

Laurent, M., Geoffroy, M., Pavani, G., & Guiraud, S. (2024). CRISPR-based gene therapies: From preclinical to clinical treatments. Cells, 13(10), 800. https://doi.org/10.3390/cells13100800

Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biology, 15, 554. https://doi.org/10.1186/s13059-014-0554-4

Lin, J., & Wong, K.-C. (2018). Off-target predictions in CRISPR-Cas9 gene editing using deep learning. Bioinformatics, 34(17), i656–i663. https://doi.org/10.1093/bioinformatics/bty554

Lin, Z., Akin, H., Rao, R., Hie, B., Zhu, Z., Lu, W., Smetanin, N., Verkuil, R., Kabeli, O., Shmueli, Y., Santos Costa, A. dos, Fazel-Zarandi, M., Sercu, T., Candela, S., & Rives, A. (2023). Evolutionary-scale prediction of atomic-level protein structure with a language model. Science, 379(6637), 1123–1130. https://doi.org/10.1126/science.ade2574

Lippman, A. (1991). Prenatal genetic testing and screening: Constructing needs and reinforcing inequities. American Journal of Law & Medicine, 17(1–2), 15–50. https://doi.org/10.1017/S0098858800007917

Listgarten, J., Weinstein, M., Kleinstiver, B. P., Sousa, A. A., Joung, J. K., Crawford, J., Gao, K., Hoang, L., Elibol, M., Doench, J. G., & Fusi, N. (2018). Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nature Biomedical Engineering, 2(1), 38–47. https://doi.org/10.1038/s41551-017-0178-6

Liu, J.-J., Orlova, N., Oakes, B. L., Ma, E., Spinner, H. B., Baez, K. L. M., Duber, J., Schoeb, F., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F., Doudna, J. A., & Banfield, J. F. (2019). CasX enzymes comprise a distinct family of RNA-guided genome editors. Nature, 566(7743), 218–223. https://doi.org/10.1038/s41586-019-0908-x

Liu, L., Xiong, Y., Zheng, Z., Huang, L., Song, J., Lin, Q., Tang, B., & Wong, K.-C. (2024). AutoCancer as an automated multimodal framework for early cancer detection. iScience, 27(7), 110183. https://doi.org/10.1016/j.isci.2024.110183

Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., & Seiden, M. V. (2020). Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 31(6), 745–759. https://doi.org/10.1016/j.annonc.2020.02.011

London, A. J. (2019). Artificial intelligence and black-box medical decisions: Accuracy versus explainability. Hastings Center Report, 49(1), 15–21. https://doi.org/10.1002/hast.973

Lotfollahi, M., Klimovskaia Susmelj, A., De Donno, C., Xia, L., et al. (2023). Predicting cellular responses to complex perturbations in high-throughput screens. Molecular Systems Biology, 19, e11517. https://doi.org/10.15252/msb.202211517

Low, C. A., Dey, A. K., Ferreira, D., Kamarck, T., Sun, W., Bae, S., & Doryab, A. (2020). Behavioral and physiological data from wearable sensors: Feasibility and acceptability in cancer survivors. PLOS ONE, 15(9), e0237698. https://doi.org/10.1371/journal.pone.0237698

Lu, N. (2023). Know thy cell-free DNA: Early detection of microsatellite instability using ultra-low-pass cell-free DNA sequences [Master’s thesis, Massachusetts Institute of Technology]. https://dspace.mit.edu/handle/1721.1/151965

Luo, Y. et al. (2024). Interpretable CRISPR/Cas9 off-target activities with mismatches and indels prediction using BERT. Computers in Biology and Medicine, 169, 107932. https://doi.org/10.1016/j.compbiomed.2024.107932

Lynch, H. T., Snyder, C. L., Shaw, T. G., Heinen, C. D., & Hitchins, M. P. (2015). Milestones of Lynch syndrome: 1895–2015. Nature Reviews Cancer, 15(3), 181–194. https://doi.org/10.1038/nrc3878

Mackenzie, C., & Stoljar, N. (Eds.). (2000). Relational autonomy: Feminist perspectives on autonomy, agency, and the social self. Oxford University Press.

Madani, A., Krause, B., Greene, E. R., Subramanian, S., Mohr, B. P., Holton, J. M., Olmos, J. L., Xiong, C., Sun, Z. Z., Socher, R., Fraser, J. S., & Naik, N. (2023). Large language models generate functional protein sequences across diverse families. Nature Biotechnology, 41, 1099–1106. https://doi.org/10.1038/s41587-022-01618-2

Makary, M., & Prasad, V. (2025). A new regulatory pathway for bespoke genetic therapies. New England Journal of Medicine.

Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823–826. https://doi.org/10.1126/science.1232033

Martani, A., Weij, F. van der, Baalen, S. van, & Beers, B. van. (2025). Repoliticizing heritable human genome editing: Discursive narrowing and technomoral change in the international debate on human germline modification. New Genetics and Society, 44(1). https://doi.org/10.1080/14636778.2025.2598071

Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M., & Daly, M. J. (2019). Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics, 51(4), 584–591. https://doi.org/10.1038/s41588-019-0379-x

Mathios, D., Johansen, J. S., Cristiano, S., Medina, J. E., Phallen, J., Larsen, K. R., Bruhm, D. C., Niknafs, N., Ferreira, L., Adleff, V., Chiao, J. Y., Leal, A., Noe, M., White, J. R., Arun, A. S., Hruban, C., Annapragada, A. V., Jensen, S. Ø., Ørntoft, M.-B. V., & Velculescu, V. E. (2021). Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nature Communications, 12(1), 5060. https://doi.org/10.1038/s41467-021-24994-w

Mavaddat, N., Michailidou, K., Dennis, J., Lush, M., Fachal, L., Lee, A., Tyrer, J. P., et al. (2019). Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. American Journal of Human Genetics, 104(1), 21–34. https://doi.org/10.1016/j.ajhg.2018.11.002

Mazzucato, M. (2013). The entrepreneurial state: Debunking public vs. Private sector myths. Anthem Press.

Mbembe, A. (2017). Critique of black reason. Duke University Press. https://doi.org/10.1215/9780822373230

Medical Device Coordination Group. (2025). MDCG 2025-6: Interplay between the Medical Devices Regulation (MDR) & In Vitro Diagnostic Medical Devices Regulation (IVDR) and the Artificial Intelligence Act (AIA).

Medicines and Healthcare products Regulatory Agency. (2024). AI airlock: The regulatory sandbox for AIaMD. GOV.UK. https://www.gov.uk/government/collections/ai-airlock-the-regulatory-sandbox-for-aiamd

Medicines and Healthcare products Regulatory Agency. (2025). Regulatory framework for point of care manufacturing. GOV.UK. https://www.gov.uk/government/publications/point-of-care-manufacturing-regulatory-framework

Meier, J., Rao, R., Verkuil, R., Liu, J., Sercu, T., & Rives, A. (2021). Language models enable zero-shot prediction of the effects of mutations on protein function. Advances in Neural Information Processing Systems, 34, 29287–29303. https://proceedings.neurips.cc/paper_files/paper/2021/file/f51338d736f95dd42427296047067694-Paper.pdf

Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M. (2018). The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Measures, 9, 353–367. https://doi.org/10.2147/PROM.S156279

Mittelstadt, B. D., Allo, P., Taddeo, M., Wachter, S., & Floridi, L. (2016). The ethics of algorithms: Mapping the debate. Big Data & Society, 3(2), 1–21. https://doi.org/10.1177/2053951716679679

Mojica, F. J. M., Díez-Villaseñor, C., García-Martínez, J., & Soria, E. (2005). Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of Molecular Evolution, 60(2), 174–182. https://doi.org/10.1007/s00239-004-0046-3

Mol, A. (1999). Ontological politics: A word and some questions. The Sociological Review, 47(S1), 74–89. https://doi.org/10.1111/j.1467-954X.1999.tb03483.x

Møller, P., Seppälä, T., Bernstein, I., Holinski-Feder, E., Sala, P., Evans, D. G., Lindblom, A., Macrae, F., Blanco, I., Jeffries, J., Vasen, H., Burn, J., Nakken, S., Hovig, E., Rodland, E. A., Tharmaratnam, K., Vos Tot Nederveen Cappel, W. H. de, Hill, J., Wijnen, J., et al.others. (2017). Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: First report from the prospective lynch syndrome database. Gut, 66(3), 464–472. https://doi.org/10.1136/gutjnl-2015-309675

Moreno-Mateos, M. A., Vejnar, C. E., Beaudoin, J.-D., Fernandez, J. P., Mis, E. K., Khokha, M. K., & Giraldez, A. J. (2015). CRISPRscan: Designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nature Methods, 12(10), 982–988. https://doi.org/10.1038/nmeth.3543

Musunuru, K., Urnov, F., Giannikopoulos, P., et al. (2025). First personalised CRISPR therapy administered to an infant with CPS1 deficiency. Reported by Innovative Genomics Institute and Children’s Hospital of Philadelphia.

Naldini, L. (2015). Gene therapy returns to centre stage. Nature, 526(7573), 351–360. https://doi.org/10.1038/nature15818

National Academies of Sciences, Engineering, and Medicine. (2017). Human genome editing: Science, ethics, and governance. The National Academies Press. https://doi.org/10.17226/24623

Nayfach, S., Bhatnagar, A., Novichkov, A., Estevam, G. O., Kim, N., Hill, E., Ruffolo, J. A., Silverstein, R., Gallagher, J., Kleinstiver, B., Meeske, A. J., Cameron, P., & Madani, A. (2025). Engineering of CRISPR-Cas PAM recognition using deep learning of vast evolutionary data. bioRxiv. https://doi.org/10.1101/2025.01.06.631536

Nelson, J. W., Randolph, P. B., Shen, S. P., Everette, K. A., Chen, P. J., Anzalone, A. V., An, M., Newby, G. A., Chen, J. C., Hsu, A., & Liu, D. R. (2022). Engineered pegRNAs improve prime editing efficiency. Nature Biotechnology, 40(3), 402–410. https://doi.org/10.1038/s41587-021-01039-7

Newby, G. A., Yen, J. S., Woodard, K. J., Mayuranathan, T., Lazzarotto, C. R., Li, Y., Sheppard-Tillman, H., Porter, S. N., Yao, Y., et al. (2021). Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature, 595, 295–302. https://doi.org/10.1038/s41586-021-03609-w

Nguengang Wakap, S., Lambert, D. M., Olry, A., Rodwell, C., Gueydan, C., Lanneau, V., Murphy, D., Le Cam, Y., & Rath, A. (2020). Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. European Journal of Human Genetics, 28, 165–173. https://doi.org/10.1038/s41431-019-0508-0

Nguyen, E., Poli, M., Durrant, M. G., Thomas, A. W., Kang, B., Sullivan, J., Ng, M. Y., Lewis, A., Patel, A., Lou, A., Erber, S., et al. (2024). Sequence modeling and design from molecular to genome scale with Evo. Science, 386(6723), eado9336. https://doi.org/10.1126/science.ado9336

NHS England. (2025). Revolutionary gene editing therapy for sickle cell. https://www.england.nhs.uk/2025/01/revolutionary-gene-editing-therapy-for-sickle-cell/.

Ni, Y., Kennebeck, S., Dexheimer, J. W., McAneney, C. M., Tang, H., Lingren, T., Li, Q., Zhai, H., & Solti, I. (2015). Automated clinical trial eligibility prescreening: Increasing the efficiency of patient identification for clinical trials in the emergency department. Journal of the American Medical Informatics Association, 22(1), 166–178. https://doi.org/10.1136/amiajnl-2014-002887

Nickel, R. S., Maher, J. Y., Hsieh, M. H., Davis, M. F., Hsieh, M. M., & Pecker, L. H. (2022). Fertility after curative therapy for sickle cell disease: A comprehensive review to guide care. Journal of Clinical Medicine, 11(9), 2318. https://doi.org/10.3390/jcm11092318

Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 156(5), 935–949. https://doi.org/10.1016/j.cell.2014.02.001

Nishimasu, H., Shi, X., Ishiguro, S., Gao, L., Hirano, S., Okazaki, S., Noda, T., Abudayyeh, O. O., Gootenberg, J. S., Mori, H., Oura, S., Holmes, B., Tanaka, M., Seki, M., Hirano, H., Aburatani, H., Ishitani, R., Ikawa, M., Yachie, N., … Nureki, O. (2018). Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science, 361(6408), 1259–1262. https://doi.org/10.1126/science.aas9129

Niu, B., Ye, K., Zhang, Q., Lu, C., Xie, M., McLellan, M. D., Wendl, M. C., & Ding, L. (2014). MSIsensor: Microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics, 30(7), 1015–1016. https://doi.org/10.1093/bioinformatics/btt755

Norman, T. M., Horlbeck, M. A., Replogle, J. M., Ge, A. Y., Xu, A., Jost, M., Gilbert, L. A., & Weissman, J. S. (2019). Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. Science, 365(6455), 786–793. https://doi.org/10.1126/science.aax4438

Novas, C. (2006). The political economy of hope: Patients’ organizations, science and biovalue. BioSocieties, 1(3), 289–305. https://doi.org/10.1017/S1745855206003024

Nuffield Council on Bioethics. (2018b). Genome editing and human reproduction: Social and ethical issues.

Nuffield Council on Bioethics. (2018a). Genome editing and human reproduction: Social and ethical issues. Nuffield Council on Bioethics. https://www.nuffieldbioethics.org/publications/genome-editing-and-human-reproduction

Nuñez, J. K., Chen, J., Pommier, G. C., Cogan, J. Z., Replogle, J. M., Adriaens, C., Ramadoss, G. N., Shi, Q., Hung, K.-L., Samelson, A. J., Pogson, A. N., Kim, J. Y. S., Chung, A., Leonetti, M. D., Chang, H. Y., Kampmann, M., Bernstein, B. E., Hovestadt, V., Gilbert, L. A., & Weissman, J. S. (2021). Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell, 184(9), 2503–2519. https://doi.org/10.1016/j.cell.2021.03.025

O’Donnell, T. J., Rubinsteyn, A., & Laserson, U. (2020). MHCflurry 2.0: Improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Systems, 11(1), 42–48.e7. https://doi.org/10.1016/j.cels.2020.06.010

Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019). Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science, 366(6469), 1139–1143. https://doi.org/10.1126/science.aaw2900

Onnela, J.-P. (2021). Opportunities and challenges in the collection and analysis of digital phenotyping data. Neuropsychopharmacology, 46(1), 45–54. https://doi.org/10.1038/s41386-020-0771-3

Organizing Committee of the Third International Summit on Human Genome Editing. (2023). Statement by the organizing committee of the third international summit on human genome editing. Nature. https://www.nature.com/articles/d41586-023-00747-2

Ottaviano, G., Georgiadis, C., Gkazi, S. A., et al. (2022). Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Science Translational Medicine, 14(668), eabq3010. https://doi.org/10.1126/scitranslmed.abq3010

Pallaseni, A., Peets, E. M., Koeppel, J., Weller, J., Vanderstichele, T., Ho, U. L., Crepaldi, L., Leeuwen, J. van, Allen, F., & Parts, L. (2022). Predicting base editing outcomes using position-specific sequence determinants. Nucleic Acids Research, 50(6), 3551–3564. https://doi.org/10.1093/nar/gkac161

Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., Villar, S. S., Wason, J. M. S., Weir, C. J., Wheeler, G. M., Yap, C., & Jaki, T. (2018). Adaptive designs in clinical trials: Why use them, and how to run and report them. BMC Medicine, 16, 29. https://doi.org/10.1186/s12916-018-1017-7

Parens, E. (1998). Is better always good? The enhancement project. In E. Parens (Ed.), Enhancing human traits: Ethical and social implications (pp. 1–28). Georgetown University Press.

Parens, E., & Asch, A. (2000). The disability rights critique of prenatal genetic testing: Reflections and recommendations. In E. Parens & A. Asch (Eds.), Prenatal testing and disability rights (pp. 3–43). Georgetown University Press.

Parliamentary Assembly of the Council of Europe. (2023). Heritable genome editing in human beings.

Pausch, P., Al-Shayeb, B., Biber, E., Cress, B. J., Sato, K., Chen, J., Banfield, J. F., & Doudna, J. A. (2020). CRISPR-CasΦ from huge phages is a hypercompact genome editor. Science, 369(6501), 333–337. https://doi.org/10.1126/science.abb1400

Petryna, A. (2009). When experiments travel: Clinical trials and the global search for human subjects. Princeton University Press.

Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J., Anagnostou, V., Fiksel, J., Cristiano, S., Papp, E., Speir, S., Reinert, T., Orntoft, M.-B. W., Woodward, B. D., Murphy, D., Parpart-Li, S., Riley, D., Nesselbush, M., Sengamalay, N., … Velculescu, V. E. (2017). Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 9(403), eaan2415. https://doi.org/10.1126/scitranslmed.aan2415

Picard, M., Scott-Boyer, M.-P., Bodein, A., Pépin, S., & Droit, A. (2021). Integration strategies of multi-omics data for machine learning analysis. Computational and Structural Biotechnology Journal, 19, 3735–3746. https://doi.org/10.1016/j.csbj.2021.06.030

Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017). Sickle cell disease. New England Journal of Medicine, 376(16), 1561–1573. https://doi.org/10.1056/NEJMra1510865

Popejoy, A. B., & Fullerton, S. M. (2016). Genomics is failing on diversity. Nature, 538(7624), 161–164. https://doi.org/10.1038/538161a

Porter, T. M. (1995). Trust in numbers: The pursuit of objectivity in science and public life. Princeton University Press.

Prainsack, B., & Buyx, A. (2017). Solidarity in biomedicine and beyond. Cambridge University Press. https://doi.org/10.1017/9781139696593

President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. (1982). Splicing life: A report on the social and ethical issues of genetic engineering with human beings. US Government Printing Office.

Pukkala, E., Engholm, G., Hojsgaard Schmidt, L. K., Storm, H., Khan, S., Lambe, M., Pettersson, D., Olafsdottir, E., Tryggvadottir, L., Hakama, M., Tsnomaki, E., Bray, F., & Klint, Å. (2018). Nordic cancer registries – an overview of their procedures and data comparability. Acta Oncologica, 57(4), 440–455. https://doi.org/10.1080/0284186X.2017.1407039

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168

Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

Rabeharisoa, V., Moreira, T., & Akrich, M. (2014). Evidence-based activism: Patients’, users’ and activists’ groups in knowledge society. In BioSocieties (Vol. 9, pp. 111–128). https://doi.org/10.1057/biosoc.2014.2

Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259

Rees, H. A., & Liu, D. R. (2018). Base editing: Precision chemistry on the genome and transcriptome of living cells. Nature Reviews Genetics, 19(12), 770–788. https://doi.org/10.1038/s41576-018-0059-1

Replogle, J. M., Saunders, R. A., Pogson, A. N., Hussmann, J. A., Lenail, A., Guna, A., Mascibroda, L., Wagner, E. J., Adelman, K., Lithwick-Yanai, G., Bren-Rickson, E., Norman, T. M., & Weissman, J. S. (2022). Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell, 185(14), 2559–2575.e28. https://doi.org/10.1016/j.cell.2022.05.013

Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020). NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Research, 48(W1), W449–W454. https://doi.org/10.1093/nar/gkaa379

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., & Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405–424. https://doi.org/10.1038/gim.2015.30

Richter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., Doudna, J. A., & Liu, D. R. (2020). Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nature Biotechnology, 38(7), 883–891. https://doi.org/10.1038/s41587-020-0453-z

Rieke, N., Hancox, J., Li, W., Milletari, F., Roth, H. R., Albarqouni, S., Bakas, S., Galtier, M. N., Landman, B. A., Maier-Hein, K., Ourselin, S., Sheller, M., Summers, R. M., Trask, A., Xu, D., Baust, M., & Cardoso, M. J. (2020). The future of digital health with federated learning. Npj Digital Medicine, 3, 119. https://doi.org/10.1038/s41746-020-00323-1

Riesselman, A. J., Ingraham, J. B., & Marks, D. S. (2018). Deep generative models of genetic variation capture the effects of mutations. Nature Methods, 15, 816–822. https://doi.org/10.1038/s41592-018-0138-4

Ringland, G. (1998). Scenario planning: Managing for the future. John Wiley & Sons.

Rizopoulos, D. (2012). Joint models for longitudinal and time-to-event data: With applications in R. Chapman; Hall/CRC.

Roache, R., & Clarke, S. (2009). Bioconservatism, bioliberalism, and the wisdom of reflecting on repugnance. In Monash bioethics review (Vol. 28, pp. 1–21). https://doi.org/10.1007/BF03351306

Robertson, J. A. (1994). Children of choice: Freedom and the new reproductive technologies. Princeton University Press.

Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., Tobin, V., Nguyen, D. N., Lee, M. R., Putnam, A. L., Ferris, A. L., Chen, J. W., Schickel, J.-N., Pellerin, L., Carmody, D., … Marson, A. (2018). Reprogramming human T cell function and specificity with non-viral genome targeting. Nature, 559, 405–409. https://doi.org/10.1038/s41586-018-0326-5

Ruffolo, J. A., & Madani, A. (2024). Designing proteins with language models. Nature Biotechnology, 42, 200–202. https://doi.org/10.1038/s41587-024-02123-4

Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014). Microsatellite instability detection by next generation sequencing. Clinical Chemistry, 60(9), 1192–1199. https://doi.org/10.1373/clinchem.2014.223677

Sandel, M. J. (2007). The case against perfection: Ethics in the age of genetic engineering. Harvard University Press.

Savulescu, J. (2005). New breeds of humans: The moral obligation to enhance. Reproductive BioMedicine Online, 10(Suppl 1), 36–39. https://doi.org/10.1016/S1472-6483(10)62202-X

Savulescu, J., Pugh, J., Douglas, T., & Gyngell, C. (2015). The moral imperative to continue gene editing research on human embryos. Protein & Cell, 6(7), 476–479. https://doi.org/10.1007/s13238-015-0184-y

Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M., Trapani, I., & Büning, H. (2023). A new age of precision gene therapy. Lancet, 403(10426), 568–582. https://doi.org/10.1016/S0140-6736(23)01952-9

Schauer, F. (1985). Slippery slopes. Harvard Law Review, 99(2), 361–383. https://doi.org/10.2307/1341127

Scheufele, D. A., Xenos, M. A., Howell, E. L., Rose, K. M., Brossard, D., & Hardy, B. W. (2017). U.S. Attitudes on human genome editing. Science, 357(6351), 553–554. https://doi.org/10.1126/science.aan3708

Schmiedel, J. M., & Lehner, B. (2019). Determining protein structures using deep mutagenesis. Nature Genetics, 51(7), 1177–1186. https://doi.org/10.1038/s41588-019-0431-x

Schwartz, P. (1991). The art of the long view: Planning for the future in an uncertain world. Doubleday.

Scientific Advice Mechanism High Level Group of Scientific Advisors. (2018). A scientific perspective on the regulatory status of products derived from gene editing and the implications for the GMO directive.

Seale, C., & Gonçalves, J. P. (2025). X-CRISP: Domain-adaptable and interpretable CRISPR repair outcome prediction. Bioinformatics Advances, 5(1), vbaf157. https://doi.org/10.1093/bioadv/vbaf157

Shakespeare, T. (2006). Disability rights and wrongs. Routledge. https://doi.org/10.4324/9780203640098

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., & Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343(6166), 84–87. https://doi.org/10.1126/science.1247005

Sharma, A., Locatelli, F., Bhatia, M., et al. (2025). Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. Blood Advances, 9(24), 6481–6490. https://doi.org/10.1182/bloodadvances.2025016701

Sheller, M. J., Edwards, B., Reina, G. A., Martin, J., Pati, S., Kotrotsou, A., Milchenko, M., Xu, W., Marcus, D., Colen, R. R., & Bakas, S. (2020). Federated learning in medicine: Facilitating multi-institutional collaborations without sharing patient data. Scientific Reports, 10, 12598. https://doi.org/10.1038/s41598-020-69250-1

Shen, M. W., Arbab, M., Hsu, J. Y., Worstell, D., Culbertson, S. J., Krabbe, O., Cassa, C. A., Liu, D. R., Gifford, D. K., & Sherwood, R. I. (2018). Predictable and precise template-free CRISPR editing of pathogenic variants. Nature, 563(7733), 646–651. https://doi.org/10.1038/s41586-018-0686-x

Sherkow, J. S. (2017). Patent protection for CRISPR: An ELSI review. Journal of Law and the Biosciences, 4(3), 565–576. https://doi.org/10.1093/jlb/lsx036

Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., Shuren, J., Temple, R., Woodcock, J., Yue, L. Q., & Califf, R. M. (2016). Real-world evidence – what is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297. https://doi.org/10.1056/NEJMsb1609216

Shields, B. J., Stevens, J., Li, J., Parasram, M., Damber, F., Janey, J. M., Adams, A., & Gonzalez, J. (2021). Bayesian reaction optimization as a tool for chemical synthesis. Nature, 590, 89–96. https://doi.org/10.1038/s41586-021-03213-y

Sibieude, E., Khandelwal, A., Girard, P., Hesthaven, J. S., & Terranova, N. (2022). Population pharmacokinetic model selection assisted by machine learning. Journal of Pharmacokinetics and Pharmacodynamics, 49, 257–270. https://doi.org/10.1007/s10928-021-09793-6

Sirugo, G., Williams, S. M., & Tishkoff, S. A. (2019). The missing diversity in human genetic studies. Cell, 177(1), 26–31. https://doi.org/10.1016/j.cell.2019.02.048

Sloot, B. van der, Vetter, A., & Zilgalvis, P. (2024). The EU Artificial Intelligence Act (2024): Implications for healthcare. Health Policy, 149, 105173. https://doi.org/10.1016/j.healthpol.2024.105173

Song, M., Kim, H. K., Lee, S., Kim, Y., Seo, S.-Y., Park, J., Choi, J. W., Jang, H., Shin, J. H., Min, S., Quan, Z., Kim, J. H., Kang, H. C., Yoon, S., & Kim, H. H. (2020). Sequence-specific prediction of the efficiencies of adenine and cytosine base editors. Nature Biotechnology, 38(9), 1037–1043. https://doi.org/10.1038/s41587-020-0573-5

Sovacool, B. K., & Hess, D. J. (2017). Ordering theories: Typologies and conceptual frameworks for sociotechnical change. Social Studies of Science, 47(5), 703–750. https://doi.org/10.1177/0306312717709363

Star, S. L., & Griesemer, J. R. (1989). Institutional ecology, “translations” and boundary objects: Amateurs and professionals in Berkeley’s Museum of Vertebrate Zoology, 1907–39. Social Studies of Science, 19(3), 387–420. https://doi.org/10.1177/030631289019003001

State Council of the People’s Republic of China. (2019). Administrative regulations on human genetic resources management.

Stilgoe, J., Owen, R., & Macnaghten, P. (2013a). Developing a framework for responsible innovation. Research Policy, 42(9), 1568–1580. https://doi.org/10.1016/j.respol.2013.05.008

Stilgoe, J., Owen, R., & Macnaghten, P. (2013b). Developing a framework for responsible research and innovation. Research Policy, 42(9), 1568–1580. https://doi.org/10.1016/j.respol.2013.05.008

Strecker, J., Jones, S., Koopal, B., Schmid-Burgk, J., Zetsche, B., Gao, L., Makarova, K. S., Koonin, E. V., & Zhang, F. (2019). Engineering of CRISPR–Cas12b for human genome editing. Nature Communications, 10, 212. https://doi.org/10.1038/s41467-018-08224-4

Sykora, P., & Caplan, A. (2017). The Council of Europe should not reaffirm the ban on germline genome editing in humans. EMBO Reports, 18(11), 1871–1872. https://doi.org/10.15252/embr.201745246

The ASCO Post Staff. (2026). New European project cluster EARLYSCAN launched to advance early detection of heritable cancers. https://ascopost.com/news/february-2026/new-european-project-cluster-earlyscan-launched-to-advance-early-detection-of-heritable-cancers/.

Thean, D. G. L., Chu, H. Y., Fong, J. H. C., Chan, B. K. C., Zhou, P., Kwok, C. C. S., Chan, Y. M., Mak, S. Y. L., Choi, G. C. G., Ho, J. W. K., Zheng, Z., & Wong, A. S. L. (2022). Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities. Nature Communications, 13(1), 2219. https://doi.org/10.1038/s41467-022-29874-5

Thielen, F. W., Meijden, C. M. van der, Meulen, P. van der, et al. (2022). Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for libmeldy and zolgensma. Cytotherapy, 24(12), 1245–1258. https://doi.org/10.1016/j.jcyt.2022.09.002

Thorlund, K., Dron, L., Park, J. J. H., & Mills, E. J. (2020). Synthetic and external controls in clinical trials – a primer for researchers. Clinical Pharmacology & Therapeutics, 107(4), 883–891. https://doi.org/10.1002/cpt.1742

Thorlund, K., Haggstrom, J., Park, J. J. H., & Mills, E. J. (2018). Key design considerations for adaptive clinical trials: A primer for clinicians. BMJ, 360, k698. https://doi.org/10.1136/bmj.k698

Timmermans, S., & Berg, M. (2003). The gold standard: The challenge of evidence-based medicine and standardization in health care. Temple University Press.

Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

Torous, J., Kiang, M. V., Lorme, J., & Onnela, J.-P. (2016). New tools for new research in psychiatry: A scalable and customizable platform to empower data driven smartphone research. JMIR Mental Health, 3(2), e16. https://doi.org/10.2196/mental.5165

Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (2017). CIRCLE-seq: A highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets. Nature Methods, 14(6), 607–614. https://doi.org/10.1038/nmeth.4278

Tsai, S. Q., Zheng, Z., Nguyen, N. T., Lieber, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khaber, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K. (2015). GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnology, 33(2), 187–197. https://doi.org/10.1038/nbt.3117

UK Government. (2015). The human fertilisation and embryology (mitochondrial donation) regulations 2015. https://www.legislation.gov.uk/uksi/2015/572/contents/made

UK Parliament. (1990). Human fertilisation and embryology act 1990. https://www.legislation.gov.uk/ukpga/1990/37

U.S. Food and Drug Administration. (2018). Framework for FDA’s real-world evidence program. https://www.fda.gov/media/120060/download.

U.S. Food and Drug Administration. (2019a). Adaptive designs for clinical trials of drugs and biologics: Guidance for industry. FDA Guidance Document.

U.S. Food and Drug Administration. (2019b). Proposed regulatory framework for modifications to artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD).

U.S. Food and Drug Administration. (2023). FDA approves first gene therapies to treat sickle cell disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-sickle-cell-disease

U.S. Food and Drug Administration. (2024a). Regenerative medicine advanced therapy designation. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation

U.S. Food and Drug Administration. (2024b). Human gene therapy products incorporating human genome editing. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-products-incorporating-human-genome-editing

VanderWeele, T. J. (2016). Mediation analysis: A practitioner’s guide. Annual Review of Public Health, 37, 17–32. https://doi.org/10.1146/annurev-publhealth-032315-021402

Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., Žı́dek, A., Green, T., Tunyasuvunakool, K., Petersen, S., Jumper, J., Clancy, E., Green, R., Vora, A., Lutfi, M., … Velankar, S. (2022). AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Research, 50(D1), D439–D444. https://doi.org/10.1093/nar/gkab1061

Vaswani, A., Shazeer, N., Parmar, N., Uszkoreit, J., Jones, L., Gomez, A. N., Kaiser, Ł., & Polosukhin, I. (2017). Attention is all you need. Advances in Neural Information Processing Systems, 30, 5998–6008. https://doi.org/10.48550/arXiv.1706.03762

Velupillai, S., Suominen, H., Liakata, M., Roberts, A., Shah, A. D., Morley, K., Osborn, D., Hayes, J., Stewart, R., Downs, J., Chapman, W., & Dutta, R. (2018). Using clinical Natural Language Processing for health outcomes research: Overview and actionable suggestions for future advances. Journal of Biomedical Informatics, 88, 11–19. https://doi.org/10.1016/j.jbi.2018.10.005

Verghese, A., Shah, N. H., & Harrington, R. A. (2018). What this computer needs is a physician: Humanism and artificial intelligence. JAMA, 319(1), 19–20. https://doi.org/10.1001/jama.2017.19198

Vertex Pharmaceuticals. (2025). Vertex presents new data on CASGEVY, including first-ever data in children ages 5–11 years, at the American Society of Hematology Annual Meeting. https://news.vrtx.com/news-releases/news-release-details/vertex-presents-new-data-casgevyr-including-first-ever-data.

Vertex Pharmaceuticals and CRISPR Therapeutics. (2023). CASGEVY (exagamglogene autotemcel) approved by FDA for treatment of sickle cell disease and transfusion-dependent beta thalassemia. Press release.

Vertex Pharmaceuticals, & CRISPR Therapeutics. (2023). Vertex and CRISPR Therapeutics announce US FDA approval of CASGEVY for the treatment of sickle cell disease.

Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., & Thompson, L. (2014). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics, 13(1), 41–54. https://doi.org/10.1002/pst.1589

Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J. (2017). 10 years of GWAS discovery: Biology, function, and translation. American Journal of Human Genetics, 101(1), 5–22. https://doi.org/10.1016/j.ajhg.2017.06.005

Vives-Vallés, J. A., & Collonnier, C. (2020). The judgment of the CJEU of 25 july 2018 on mutagenesis: Interpretation and interim legislative proposal. Frontiers in Plant Science, 10, 1813. https://doi.org/10.3389/fpls.2019.01813

Vojta, A., Dobrinić, P., Tadić, V., Bočkor, L., Korać, P., Julg, B., Klasić, M., & Zoldoš, V. (2016). Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Research, 44(12), 5615–5628. https://doi.org/10.1093/nar/gkw159

Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schweizer, M. (2019). High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nature Medicine, 25(2), 242–248. https://doi.org/10.1038/s41591-018-0204-6

Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020). Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science, 368(6488), eaba8853. https://doi.org/10.1126/science.aba8853

Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223–238. https://doi.org/10.1038/nrc.2017.7

Wang, D., Zhang, F., & Gao, G. (2020). CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. Cell, 181(1), 136–150. https://doi.org/10.1016/j.cell.2020.03.023

Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. Science, 343(6166), 80–84. https://doi.org/10.1126/science.1246981

Wang, Y., Sohn, S., & Liu, H. (2022). CancerBERT: A cancer domain-specific language model for extracting cancer phenotypes from clinical text. Journal of Biomedical Informatics, 130, 104072. https://doi.org/10.1016/j.jbi.2022.104072

Wang, Y., Wang, L., Rastegar-Mojarad, M., Moon, S., Shen, F., Afzal, N., Liu, S., Zeng, Y., Mehrabi, S., Sohn, S., & Liu, H. (2018). Clinical information extraction applications: A literature review. Journal of Biomedical Informatics, 77, 34–49. https://doi.org/10.1016/j.jbi.2017.11.011

Wasmer, M. (2019). Roads forward for european GMO policy — uncertainties in wake of ECJ judgment have to be mitigated by regulatory reform. Frontiers in Bioengineering and Biotechnology, 7, 132. https://doi.org/10.3389/fbioe.2019.00132

Wienert, B., Wyman, S. K., Richardson, C. D., Yeh, C. D., Akcakaya, P., Porritt, M. J., Morlock, M., Vu, J. T., Kazane, K. R., Watry, H. L., Judge, L. M., Conklin, B. R., Maresca, M., & Corn, J. E. (2019). Unbiased detection of CRISPR off-targets in vivo using DISCOVER-seq. Science, 364(6437), 286–289. https://doi.org/10.1126/science.aav9023

Wilkinson, A., & Kupers, R. (2014). The essence of scenarios: Learning from the shell experience. Amsterdam University Press. https://doi.org/10.5117/9789089646927

Winner, L. (1980). Do artifacts have politics? Daedalus, 109(1), 121–136. https://www.jstor.org/stable/20024652

Wishart, D. S. (2019). Metabolomics for investigating physiological and pathophysiological processes. Physiological Reviews, 99(4), 1819–1875. https://doi.org/10.1152/physrev.00035.2018

World Health Organization. (2021b). Human genome editing: A framework for governance. https://www.who.int/publications/i/item/9789240030060

World Health Organization. (2021a). Human genome editing: A framework for governance. World Health Organization.

World Health Organization. (2021c). Human genome editing: recommendations. https://www.who.int/publications/i/item/9789240030381

Wu, W., Yang, J., Tan, Y., Gu, K., Shen, Q., Yang, C., Hu, M., Xiang, Y., & Xu, W. (2025). Cost-effectiveness of colorectal cancer screening under different scenarios of colonoscopy adherence: A microsimulation study. BMJ Public Health, 3(1), e001344. https://doi.org/10.1136/bmjph-2024-001344

Wu, Y., Zeng, J., Roscoe, B. P., et al. (2019). Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine, 25(5), 776–783. https://doi.org/10.1038/s41591-019-0401-y

Yeh, C. D., Richardson, C. D., & Corn, J. E. (2019). Advances in genome editing through control of DNA repair pathways. Nature Cell Biology, 21(12), 1468–1478. https://doi.org/10.1038/s41556-019-0425-z

Yoon, J., Kim, J., Park, S., Lee, M., et al. (2025). Brief summary of the regulatory frameworks of regenerative medicine therapies. Frontiers in Pharmacology, 15, 1486812. https://doi.org/10.3389/fphar.2024.1486812

Yotova, R. (2020). Regulating genome editing under international human rights law. International and Comparative Law Quarterly, 69(3), 653–684. https://doi.org/10.1017/S0020589320000184

Young, I. M. (2011). Responsibility for justice. Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195392388.001.0001

Zeng, S., Liu, L. J., Wen, J., Yetisgen, M., Etzioni, R., & Luo, G. (2025). TrajSurv: Learning continuous latent trajectories from electronic health records for trustworthy survival prediction. Proceedings of Machine Learning for Healthcare, 298, 1–27.

Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., Oost, J. van der, Regev, A., Koonin, E. V., & Zhang, F. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 163(3), 759–771. https://doi.org/10.1016/j.cell.2015.09.038

Zhang, G., Dai, Z., & Dai, X. (2020). CRISPR-IP: A CRISPR off-target prediction tool with improved performance. Bioinformatics, 36(10), 3137–3138. https://doi.org/10.1093/bioinformatics/btaa143

Zhang, Y., Long, Y., & Kwoh, C. K. (2023). CRISPR-BERT: Enhancing CRISPR/Cas9 off-target activities with mismatches and indels prediction using BERT-based convolutional and recurrent neural networks. https://github.com/BrokenStringx/CRISPR-BERT.

Zhu, H., Richmond, E., & Liang, C. (2019). CRISPR-based tools for multiplex genome editing. Methods in Molecular Biology, 1961, 53–67. https://doi.org/10.1007/978-1-4939-9170-9_4